Loading…
Reported covered position: Chief of Staff, Rep. Mark Souder; Deputy Political Director, White House
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: RETROPHIN, INC. · Firm: COVE STRATEGIES
S.340 - CREATES Act of 2019, The Orphan Drug Act, Drug pricing, Advancing American Kidney Initiative
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: RETROPHIN, INC. · Firm: COVE STRATEGIES
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
RETROPHIN, INC. via COVE STRATEGIES
2020 · third_quarter · 3T
S. 340 - CREATES Act of 2019, The Orphan Drug Act, Drug Pricing, Advancing American Kidney Initiative
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
RETROPHIN, INC. via COVE STRATEGIES
2020 · second_quarter · Q2
Source: Senate LDA
S.340 - CREATES Act of 2019, The Orphan Drug Act, Drug pricing, Advancing American Kidney Initiative
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: RETROPHIN, INC. · Firm: COVE STRATEGIES
S. 340 - CREATES Act of 2019, The Orphan Drug Act, Drug Pricing, Advancing American Kidney Initiative
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: RETROPHIN, INC. · Firm: COVE STRATEGIES
S.340 - CREATES Act of 2019 The Orphan Drug Act Drug pricing
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: RETROPHIN, INC. · Firm: COVE STRATEGIES
S.340 - CREATES Act of 2019 The Orphan Drug Act Drug pricing
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: RETROPHIN, INC. · Firm: COVE STRATEGIES
S.340 - CREATES Act of 2019 The Orphan Drug Act Drug pricing
S.340 - CREATES Act of 2019, The Orphan Drug Act, Drug pricing, Advancing American Kidney Initiative
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
RETROPHIN, INC. via COVE STRATEGIES
2020 · first_quarter · Q1
S.340 - CREATES Act of 2019, The Orphan Drug Act, Drug pricing, Advancing American Kidney Initiative
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
RETROPHIN, INC. via COVE STRATEGIES
2019 · fourth_quarter · Q4
S.340 - CREATES Act of 2019 The Orphan Drug Act Drug pricing
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
RETROPHIN, INC. via COVE STRATEGIES
2019 · third_quarter · Q3
S.340 - CREATES Act of 2019 The Orphan Drug Act Drug pricing
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
RETROPHIN, INC. via COVE STRATEGIES
2019 · second_quarter · Q2
S.340 - CREATES Act of 2019 The Orphan Drug Act Drug pricing
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
RETROPHIN, INC. via COVE STRATEGIES
2019 · first_quarter · Q1
General issues related to rare disease and patient care
General issues related to the CREATES Act, the Orphan Drug Act, and drug pricing
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
RETROPHIN, INC. via COVE STRATEGIES
2019 · first_quarter · RR
General issues related to the Orphan Drug Act, drug pricing, rare diseases, and patient/caregiver assistance
General issues related to the Orphan Drug Act, drug pricing, rare diseases, and patient/caregiver assistance